Michael Yee Analyst PerformanceGlobal Head of Biotechnology Equity Research & Managing Director - Senior Biotechnology Analyst at UBS GroupMichael Yee is a stock analyst at UBS Group in the healthcare sector, covering 47 publicly traded companies. Over the past year, Michael Yee has issued 89 stock ratings, including strong buy, buy, and hold recommendations. While full access to Michael Yee's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Michael Yee's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings198 Last 12 YearsBuy Recommendations84.02% 163 Buy RatingsCompanies Covered47 Unique Companies Ratings Distribution194RatingsDistribution of strong buy, buy, hold, and sell ratings by Michael Yee.RatingPercentageCount Strong Buy0.5%1 ratings Buy83.5%162 ratings Hold16.0%30 ratings Sell0.0%0 ratingsOut of 194 total stock ratings issued by Michael Yee at UBS Group, the majority (83.5%) have been Buy recommendations, followed by 16.0% Hold and 0.5% Strong Buy.Best & Worst CallsBest Call0000.0%MRNAAug 2020Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%AMRNNov 2019Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ87.2% of companies on NASDAQ41 companiesNYSE12.8% of companies on NYSE6 companiesMichael Yee, an analyst at UBS Group, currently covers 47 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare47 companies100.0%Michael Yee of UBS Group specializes in stock coverage within the Healthcare sector.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY38 companies80.9%PHARMACEUTICALS8 companies17.0%HEALTHCARE TECHNOLOGY1 company2.1% Michael Yee's Ratings History at UBS Group Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsMRKMerck & Co., Inc.8/20/2026Boost Price Target$151.73$175.00Buy$0.0000.00% ROISDGRSchrodinger8/14/2026Initiated Coverage$18.46$19.00Neutral$0.0000.00% ROISDGRSchrodinger8/14/2026Initiated Coverage$18.46$19.00Neutral$0.0000.00% ROITRAXFirst Tracks Biotherapeutics8/10/2026Boost Price Target$46.70$65.00Buy$0.0000.00% ROILLYEli Lilly and Company8/7/2026Set Price Target$1,177.47$1,376.00$0.0000.00% ROIDNLIDenali Therapeutics8/7/2026Boost Price Target$24.58$34.00Buy$0.0000.00% ROIAMGNAmgen8/5/2026Boost Price Target$407.83$440.00Buy$0.0000.00% ROIBIIBBiogen7/30/2026Boost Price Target$204.32$240.00Buy$0.0000.00% ROIVRTXVertex Pharmaceuticals7/13/2026Boost Price Target$481.82$585.00Buy$0.0000.00% ROIAMGNAmgen7/13/2026Boost Price Target$358.76$420.00Buy$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. ABBVAbbVie7/13/2026Boost Price Target$246.93$260.00Neutral$0.0000.00% ROILLYEli Lilly and Company7/13/2026Boost Price Target$1,188.32$1,425.00Buy$0.0000.00% ROIORKAOruka Therapeutics7/1/2026Boost Price Target$95.17$130.00Buy$0.0000.00% ROIAPGEApogee Therapeutics6/23/2026Downgrade$132.55$135.11Neutral$0.0000.00% ROIJBIOJade Biosciences6/15/2026Initiated Coverage$15.34$45.00Buy$0.0000.00% ROIJBIOJade Biosciences6/15/2026Initiated Coverage$16.10$45.00Buy$0.0000.00% ROIPFEPfizer5/27/2026Reiterated Rating$26.34$27.00Neutral$0.0000.00% ROIANABAnaptysBio5/13/2026Boost Price Target$65.58$76.00Buy$0.0000.00% ROIORKAOruka Therapeutics4/28/2026Boost Price Target$82.12$100.00Buy$0.0000.00% ROIBIIBBiogen4/22/2026Upgrade$185.95$225.00Buy$0.0000.00% ROIANABAnaptysBio4/21/2026Lower Price Target$53.19$60.00Buy$0.0000.00% ROIAMGNAmgen4/13/2026Boost Price Target$349.82$400.00Buy$0.0000.00% ROIMRKMerck & Co., Inc.4/13/2026Boost Price Target$120.19$145.00Buy$0.0000.00% ROIPFEPfizer4/13/2026Boost Price Target$27.32$27.00Neutral$0.0000.00% ROIORKAOruka Therapeutics4/6/2026Boost Price Target$55.82$75.00Buy$0.0000.00% ROIKODKodiak Sciences3/27/2026Boost Price Target$41.92$80.00Buy$0.0000.00% ROILLYEli Lilly and Company3/18/2026Reiterated Rating$915.76Buy$0.0000.00% ROISDGRSchrodinger3/17/2026Lower Price Target$12.48$13.00Neutral$0.0000.00% ROIANABAnaptysBio3/17/2026Boost Price Target$66.88$90.00Buy$0.0000.00% ROIBMYBristol Myers Squibb3/6/2026Reiterated Rating$60.69$70.00Buy$0.0000.00% ROINUVBNuvation Bio3/3/2026Lower Price Target$4.48$7.00Neutral$0.0000.00% ROIMBXMBX Biosciences2/24/2026Reiterated Rating$37.10Buy$0.0000.00% ROIACLXArcellx2/24/2026Downgrade$113.75$115.00Neutral$0.0000.00% ROIDMRADamora Therapeutics, Inc. Common Stock2/17/2026Initiated Coverage$29.12$45.00Buy$0.0000.00% ROIABBVAbbVie2/5/2026Lower Price Target$217.41$230.00Neutral$0.0000.00% ROIABBVAbbVie2/5/2026Upgrade$220.74Hold$0.0000.00% ROILLYEli Lilly and Company2/2/2026Reiterated Rating$1,050.45Buy$0.0000.00% ROIVRTXVertex Pharmaceuticals1/26/2026Boost Price Target$473.83$545.00Buy$0.0000.00% ROIAMGNAmgen1/26/2026Boost Price Target$349.03$390.00Buy$0.0000.00% ROIGILDGilead Sciences1/26/2026Boost Price Target$137.73$155.00Buy$0.0000.00% ROIReady to give options a try? Your first trade (Ticker included) -INSIDE (Ad)Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.GILDGilead Sciences1/15/2026Reiterated Rating$122.83Buy$0.0000.00% ROIABBVAbbVie1/13/2026Reiterated Rating$220.24Neutral$0.0000.00% ROIVTYXVentyx Biosciences1/8/2026Reiterated Rating$13.73$14.00Neutral$0.0000.00% ROIVTYXVentyx Biosciences1/8/2026Downgrade$13.81$14.00Hold$0.0000.00% ROIACLXArcellx1/7/2026Initiated Coverage$62.98Buy$0.0000.00% ROIDNLIDenali Therapeutics1/7/2026Initiated Coverage$17.72Buy$0.0000.00% ROIVRDNViridian Therapeutics1/7/2026Initiated Coverage$31.05$50.00Buy$0.0000.00% ROIVTYXVentyx Biosciences1/7/2026Initiated Coverage$10.05$20.00Buy$0.0000.00% ROIALLOAllogene Therapeutics1/7/2026Initiated Coverage$1.41$8.00Buy$0.0000.00% ROIZLABZai Lab1/7/2026Initiated Coverage$18.20$35.00Buy$0.0000.00% ROISRRKScholar Rock1/7/2026Initiated Coverage$41.31$60.00Buy$0.0000.00% ROISDGRSchrodinger1/7/2026Initiated Coverage$18.79$18.00Neutral$0.0000.00% ROISABSSAB Biotherapeutics1/7/2026Initiated Coverage$3.62$7.00Buy$0.0000.00% ROIORKAOruka Therapeutics1/7/2026Initiated Coverage$26.62$50.00Buy$0.0000.00% ROIOLMAOlema Pharmaceuticals1/7/2026Initiated Coverage$25.04$45.00Buy$0.0000.00% ROINUVBNuvation Bio1/7/2026Initiated Coverage$8.47$10.00Neutral$0.0000.00% ROIKODKodiak Sciences1/7/2026Initiated Coverage$25.05$50.00Buy$0.0000.00% ROIMBXMBX Biosciences1/7/2026Initiated Coverage$28.70$60.00Buy$0.0000.00% ROIIVAInventiva1/7/2026Initiated Coverage$4.54$12.00Buy$0.0000.00% ROIIMCRImmunocore1/7/2026Set Price Target$32.85$55.00Buy$0.0000.00% ROIDNLIDenali Therapeutics1/7/2026Initiated Coverage$17.21$25.00Buy$0.0000.00% ROIBEAMBeam Therapeutics1/7/2026Initiated Coverage$28.34$28.00Neutral$0.0000.00% ROIANABAnaptysBio1/7/2026Initiated Coverage$43.91$70.00Buy$0.0000.00% ROIALGSAligos Therapeutics1/7/2026Initiated Coverage$8.76$20.00Buy$0.0000.00% ROIACLXArcellx1/7/2026Initiated Coverage$62.06$100.00Buy$0.0000.00% ROIBMYBristol Myers Squibb1/7/2026Upgrade$54.45$65.00Buy$0.0000.00% ROIGILDGilead Sciences1/7/2026Initiated Coverage$121.36$145.00Buy$0.0000.00% ROIIDYAIDEAYA Biosciences1/7/2026Initiated Coverage$37.28$50.00Buy$0.0000.00% ROIIMCRImmunocore1/7/2026Upgrade$33.76$55.00Buy$0.0000.00% ROIALGSAligos Therapeutics1/7/2026Initiated Coverage$10.33$20.00Buy$0.0000.00% ROIALLOAllogene Therapeutics1/7/2026Initiated Coverage$1.49$8.00Buy$0.0000.00% ROIAMGNAmgen1/7/2026Upgrade$330.11Strong-Buy$0.0000.00% ROIANABAnaptysBio1/7/2026Reiterated Rating$43.80$70.00Buy$0.0000.00% ROIBEAMBeam Therapeutics1/7/2026Initiated Coverage$28.00$28.00Hold$0.0000.00% ROIIVAInventiva1/7/2026Reiterated Rating$4.92$12.00Buy$0.0000.00% ROIKODKodiak Sciences1/7/2026Initiated Coverage$26.62$50.00Buy$0.0000.00% ROIMBXMBX Biosciences1/7/2026Initiated Coverage$30.72$60.00Buy$0.0000.00% ROINUVBNuvation Bio1/7/2026Initiated Coverage$8.46$10.00Hold$0.0000.00% ROIOLMAOlema Pharmaceuticals1/7/2026Initiated Coverage$25.57$45.00Buy$0.0000.00% ROIORKAOruka Therapeutics1/7/2026Initiated Coverage$26.40$50.00Buy$0.0000.00% ROISABSSAB Biotherapeutics1/7/2026Initiated Coverage$3.86$7.00Buy$0.0000.00% ROISDGRSchrodinger1/7/2026Initiated Coverage$18.61$18.00Hold$0.0000.00% ROISRRKScholar Rock1/7/2026Initiated Coverage$41.67$60.00Buy$0.0000.00% ROIVRDNViridian Therapeutics1/7/2026Initiated Coverage$30.33$50.00Buy$0.0000.00% ROIVTYXVentyx Biosciences1/7/2026Initiated Coverage$13.84$20.00Buy$0.0000.00% ROIZLABZai Lab1/7/2026Initiated Coverage$18.50$35.00Buy$0.0000.00% ROIBIIBBiogen1/6/2026Initiated Coverage$182.61$185.00Neutral$0.0000.00% ROIVRTXVertex Pharmaceuticals1/6/2026Initiated Coverage$468.58$535.00Buy$0.0000.00% ROILLYEli Lilly and Company1/6/2026Initiated Coverage$1,063.95$1,250.00Buy$0.0000.00% ROIALXOALX Oncology3/6/2025Upgrade$1.04$3.00Buy$0.0000.00% ROIReady to give options a try? Your first trade (Ticker included) -INSIDE (Ad)Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow. Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenWeiss RatingsCitigroupUBS GroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank Aktiengesellschaft Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
